

時間	LAP	プログラム
REVIEWING Day1		
10:00-10:10	10	Coordinator: Haruo Watanabe , Program supervisor/officer, AMED, JAPAN Q&A on Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
SESSION II Global AMR and Regional AMR Coordination Chair: Jane Knisely , NIAID, USA		
10:10-10:30	20	(TBD) Antimicrobial Resistance around the World Showcase presentations by e-ASIA MO AMR Research in Myanmar: Current Situation, Challenges and Ways Forward Wah Wah Aung , Director (Research), Advanced Molecular Research Centre, Department of Medical Research, Ministry of Health and Sports, MYANMAR ANTIMICROBIAL RESISTANCE (AMR) IN THE PHILIPPINES Jaime C. Montoya , Executive Director, Professor, Philippine Council for Health Research and Development (PCHRD)/ Department of Science and Technology, University of the Philippines College of Medicine (UPCM), PHIIPPINES
10:30-10:45	15	US engagement in international AMR activities Lynn Filpi , The U.S. Department of Health and Human Services / Office of the Secretary/ Office of Global Affairs (HHS/OS/OGA), USA

時間	LAP	プログラム
SESSION III Strategies for Improving Antimicrobial Drug Development Chair: Tania Sorrell , The University of Sydney, AUSTRALIA		
10:45-11:25	40	<p>Strategy for improving the development of treatments for priority drug-resistant infections Seamus O'Brien, Director of Research & Development, Global Antibiotic Research & Development Partnership (GARDP), SWITZERLAND</p> <p>Strategies for improving antimicrobial drug development for the treatment of Mycobacterium tuberculosis Matthew McNeil, Research Fellow, Department of Microbiology and Immunology, University of Otago, NEW ZEALAND</p> <p>Antimicrobial Drug Development in Japan Keiji Hirai, Senior Advisor, Kyorin Pharmaceutical Co., Ltd, JAPAN</p> <p>Alternatives to Improving Antimicrobial Drug Development Ruth Zadoks, Professor, Sydney School of Veterinary Science, The University of Sydney, AUSTRALIA</p>
PANEL DISCUSSION		
11:25-11:50	25	<p>Strategies to Prevent or Reduce AMR in One Health</p> <p>Coordinator: Haruo Watanabe, Program supervisor/officer, AMED, JAPAN</p> <p>Discussion Points (Continued from Discussion Points on Day 1):</p> <p>3. Key Strategies for Solving AMR Problems -What kind of challenges that we are facing on funding? (At country & regional levels) - What is the role of industries in forming a cooperative research network toward the development? - What kind of supporting system can be developed for the developing countries?</p> <p>4. Future Directions for AMR Research and Coordination with Relevant Activities - What kind of research network should be built and how can we do that? Who will take the leadership?</p>

時間	LAP	プログラム
CLOSING		
11:50-12:00	10	Brief Summary of Discussions and Next Steps

Panelists at Day2

- **Lynn Filpi**, The U.S. Department of Health and Human Services / Office of the Secretary/ Office of Global Affairs (HHS/OS/OGA), USA
- **Tatsuro Kuzuki**, Scientific Liaison, DNDi Japan, JAPAN
- **Ruth Zadoks**, Professor, Sydney School of Veterinary Science, The University of Sydney, AUSTRALIA
- **Matthew McNeil**, Research Fellow, Department of Microbiology and Immunology, University of Otago, NEW ZEALAND
- **Keiji Hirai**, Senior Advisor, Kyorin Pharmaceutical Co., Ltd, JAPAN
- **Tania Sorrell**, The University of Sydney, AUSTRALIA
- **Jane Knisley**, NIAID, USA
- **Li Yang Hsu**, Saw Swee Hock School of Public Health, National University of Singapore, SINGAPORE
- **Seamus O'Brien**, Director of Research & Development, Global Antibiotic Research & Development Partnership (GARDP), SWITZERLAND